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ABSTRACT
Cancer is associated with a higher risk of stroke, and in rare cases stroke can be the first manifestation of occult neoplasia. We present the 
case of a 74-year-old woman hospitalized for ischaemic stroke with multiple cerebral infarctions in several vascular territories. The exclusion 
of other aetiologies and the simultaneous presence of thromboembolic events in other organs raised the suspicion of a hypercoagulable 
state, which upon investigation revealed occult neoplasia of the lung. There was rapid deterioration, with recurrent thrombotic events 
despite anticoagulation, which eventually led to the patient’s death.
LEARNING POINTS
• Stroke can be the first manifestation of occult neoplasia.
• In the presence of cryptogenic stroke, high D-dimers, multiple brain infarctions in different vascular territories and thromboembolic 
events in other organs, the possibility of hidden neoplasia should be considered. 
• Anticoagulation in disseminated intravascular coagulation is insufficient if the primary disease is not treated.
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CASE PRESENTATION
A 74-year-old woman, with controlled hypertension and dyslipidaemia, presented to the emergency department due to altered speech, 
left-sided facial droop and decreased muscle strength on the right side of her body with 12 hours of evolution. Physical examination showed 
aphasia, central facial nerve palsy on the left side, slight right-sided hemiparesis, Babinski’s sign on the left and fever. Computed tomography 
of the head (head-CT) showed bilateral nucleocapsular and subcortical fronto-parietal ischaemic infarctions of unknown date. The 
electrocardiogram (ECG) showed sinus rhythm and the thorax x-ray a small left pleural effusion. Blood analysis showed 14,400 leucocytes/
µl, increased C-reactive protein (217.8 mg/l), LDH 459 U/l and INR 1.57. The patient was medicated with aspirin and hospitalized with 
ischaemic stroke. Blood cultures were collected. Doppler ultrasonography of the neck vessels and a trans-thoracic echocardiogram showed 
no alterations. Magnetic resonance imaging (MRI) revealed multiple acute ischaemic infarctions scattered over both cerebellar and cerebral 
hemispheres, reflecting strokes in the posterior and anterior circulations (Fig. 1). 
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Given the possibility of cardioembolic aetiology, enoxaparin was initiated (on the 7th day of hospitalization), however transoesophageal 
echocardiography showed no alterations. Neurological deficits deteriorated on the day anticoagulation was started, leading to prostration. 
Head-CT was repeated, revealing a massive parenchymal haematoma in the left frontal region which led to suspension of the enoxaparin.
After the most common stroke aetiologies were excluded, the following examinations were performed, but showed no alterations: lupus 
anticoagulant, anticardiolipin and anti-beta2-glycoprotein I antibodies, antithrombin III, proteins S and C, antineutrophil cytoplasmic 
autoantibodies, mutation of the prothrombin gene and factor V Leiden, and HIV, HBV, HCV and VDRL serologies. Antinuclear antibodies 
were positive (1:160) and D-dimers were high at 1,644 µg/l (normal <230 µg/l), while fibrinogen was low at 1.4 g/l (normal 2–4 g/l). 
A whole-body CT scan revealed a solid lesion in the left lower lobe of the left lung, multiple mediastinal pathological lymph nodes, peripheral 
lung thromboembolism with greater expression on the right, right femoropopliteal venous thrombosis and splenic and renal infarctions 
(Figs. 2–4). 
Figure 1. Diffusion-weighted magnetic resonance of the brain showing 
multiple acute ischaemic lesions in the anterior and posterior circulations
Figure 2. Contrast-enhanced CT scan of the abdomen showing splenic infarcts (red arrows)
Figure 3. Contrast-enhanced CT scan of the abdomen showing kidney infarcts (red arrows)
Figure 4. Contrast-enhanced CT scan of the thorax showing lung cancer in the left lower lobe (red arrow)
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Faced with the impossibility of resuming anticoagulation immediately, a filter was placed on the inferior vena cava. Cerebral angiography 
showed occlusion of the right internal carotid artery (recall previous normal Doppler ultrasonography of the neck vessels) and excluded 
vasculitis.
Endoscopic ultrasound-guided transoesophageal biopsy of a mediastinal lymph node revealed non-small cell lung cancer. 
Immunohistochemistry testing for the lung cancer subtype proved inconclusive.
Disseminated intravascular coagulation (DIC) with multiple brain and systemic thrombotic events was diagnosed as a manifestation of a 
paraneoplastic syndrome of the hidden lung neoplasia. With favourable evolution of the brain haemorrhage, enoxaparin was resumed 2 
weeks after the event. However, as there were new thromboembolic events despite the reintroduction of anticoagulation, it was definitively 
suspended due to progressively worsening thrombocytopenia.
During hospitalization, the patient remained feverish, with high inflammatory parameters, but no infectious source was identified and 
microbiological cultures were negative. Such alterations were considered to be correlated with systemic thromboses.
At this stage, the patient was mute and tetraparetic, with a level 4 performance status (ECOG). It was decided in a multidisciplinary meeting 
not to start cytostatics as no benefit was anticipated in view of the advanced neoplasia (stage IIIB/IV) and a high degree of dependence. The 
patient was referred to palliative care and died a few days later.
DISCUSSION
Stroke, just as venous thromboembolism (VTE), can be the first manifestation of hidden neoplasia and precede its diagnosis by several 
months[1,2].
Although the most frequent aetiology of stroke in cancer patients is related to traditional cerebrovascular risk factors, cryptogenic 
stroke is more frequent in this population[3]. In some cancer patients, stroke has certain particular characteristics suggesting underlying 
pathophysiological mechanisms other than the traditional ones, pointing towards a more direct role of cancer in the genesis of the stroke[2,3]. 
This patient had several cancer-associated ischaemic-stroke (CAIS) characteristics: cryptogenic stroke with fewer traditional cardiovascular 
risk factors, multiple acute ischaemic lesions in different cerebral vascular territories, high D-dimers and the simultaneous presence of other 
thromboembolic events[2,3]. The presence of high inflammatory parameters also appears to be a characteristic of patients with CAIS[4]. A 
stroke patient with these characteristics should therefore raise the hypothesis of hidden neoplasia. 
The hypercoagulability associated with cancer seems to be the most important mechanism in the genesis of CAIS and may manifest in its 
most severe form with DIC, a poor prognostic factor in lung cancer[1,3,5]. In this patient, paraneoplastic DIC was responsible for VTE and for 
multiple arterial thromboses in the brain, kidney and spleen. Even though enoxaparin may have contributed to brain haemorrhage, DIC 
certainly played a key role, leading not only to thrombosis but also to haemorrhage through the consumption of platelets and coagulation 
factors[1]. 
Anticoagulation is likely to be beneficial; however, the safety and efficiency of this strategy in cancer patients and DIC has yet to be evaluated 
in major clinical trials, and cases like that here portrayed illustrate how this therapy can be hard to manage[1,3], The treatment of neoplasia is 
crucial for the resolution of DIC[1,5].
Even though cancer patients are especially vulnerable, there is still a need for guidelines regarding both the prevention and treatment of 
stroke in this population[2].
REFERENCES
1.  Levi M. Management of cancer-associated disseminated intravascular coagulation. Thromb Res 2016;140(Suppl 1):S66–70. 
2.  Wang JY, Zhang GJ, Zhuo SX, Wang K, Hu XP, Zhang H, et al. D-dimer >2.785 µg/ml and multiple infarcts ≥3 vascular territories are two characteristics of identifying cancer-
associated ischemic stroke patients. Neurol Res 2018;40:948–954. 
3.  Dearborn JL, Urrutia VC, Zeiler SR. Stroke and cancer - a complicated relationship. J Neurol Transl Neurosci 2014;2:1039. 
4.  Lee EJ, Nah HW, Kwon JY, Kang DW, Kwon SU, Kim JS. Ischemic stroke in patients with cancer: is it different from usual strokes? Int J Stroke 2014;9:406–412. 
5.  Kanaji N, Mizoguchi H, Inoue T, Tadokoro A, Watanabe N, Ishii T, et al. Clinical features of patients with lung cancer accompanied by thromboembolism or disseminated 
intravascular coagulation. Ther Clin Risk Manag 2018;14:1361–1368. 
